
<strong><u>Release Date</u></strong><br/>
December 22, 2014<br/>
<br/>
<strong><u>Expiration Date</u></strong><br/>
December 22, 2015<br/>
<br/>

<strong><u>Faculty</u></strong><br>
Louis Chow, MD<strong><br>
</strong>Organisation for Oncology and Translational Research (OOTR), <br>
Hong  Kong, China
<p>Luca Gianni, MD<br>
San Raffaele Institute<strong>, <br>
</strong>Milan, Italy</p>
<p>Andreas Schneeweiss, MD<br>
National  Center for Tumor Diseases<br>
University Hospital<br>
Heidelberg, Germany<br>
<br>

<strong><u>Learning Objectives:</u></strong><br/>
After successful completion of this educational  activity, participants should be able to:</p>
<ul class="bullets">
  <li>Summarize the key new data and important developments in       neoadjuvant therapy for patients with breast cancer</li>
  <li>Discuss how these data are likely to influence current and future       practice</li>
  <li>Understand the influences of biological characteristics (eg, ER       and HER2 status) on treatment selection and likelihood of response</li>
  <li>Describe best practices for treatment selection and patient       management in the neoadjuvant setting</li>
</ul>
<br/>

<strong><u>Provider</u></strong><br/>
This activity is provided by prIME Oncology.<br/><br/>

<strong><u>Support</u></strong><br/>
<p>This educational activity is supported by a grant  from  Celgene Corporation.</p>
<strong><u>Target Audience</u></strong><br/>
This educational activity is designed for medical  oncologists, surgical and radiation oncologists, and other healthcare  professionals involved and/or interested in the management of patients with  breast cancer.<br/><br/>

<strong><u>Continuing Medical Education</u></strong><br/>
prIME Oncology is accredited by the Accreditation  Council for Continuing Medical Education (ACCME®) to provide continuing medical  education for physicians.<br>
<br>
prIME Oncology designates this enduring activity for a maximum of&nbsp;<em>XX AMA PRA Category 1  Credits</em>™<em>.&nbsp;</em>Physicians should claim only the  credit commensurate with the extent of their participation in the activity.<br/><br/>

<strong><u>Method of Participation</u></strong><br/>
<p>There are no fees for participating in and receiving  CME credit for this activity. In order to receive credit, participants must  successfully complete the online post test  and activity evaluation. Your participation in this CME activity will be  recorded in prIME Oncology&rsquo;s database. However, upon request, your CME credit  certificate will be emailed to you. Technical requirements may be found under  the&nbsp;<a href="http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx">Terms of Use</a>.</p>
<p>A link to the posttest is available on the video  player page.</p>
<p><strong>In  order to receive credit, participants must  successfully complete the online posttest with XX% or higher. </strong></p>
<strong><u>Disclosure of Relevant Financial Relationships</u></strong><br/>
prIME Oncology assesses the relevant financial  relationships of its instructors, planners, managers, and other individuals who  are in a position to control the content of CME activities.&nbsp;Any relevant  conflicts of interest that are identified are thoroughly vetted by prIME  Oncology for fairness, balance, and scientific objectivity of data, as well as  patient care recommendations. prIME Oncology is committed to providing its  learners with high-quality CME activities and related materials that promote  improvements or quality in healthcare and not a specific proprietary business  interest of a commercial entity.<br/><br/>

<strong><u>Faculty Disclosures</u></strong><br/>

<p>The faculty reported the following financial  relationships or relationships to products or devices they or their  spouses/life partners have with commercial interests related to the content of  this CME activity:</p>
<p>Dr </p>
<p>Dr</p>
<p>Dr Scheeweiss has no relevant financial  relationships to disclose. He has agreed to disclose any unlabeled/unapproved  uses of drugs or products referenced in his presentation.</p>
<p>The employees of prIME Oncology have disclosed:</p>
<ul class="bullets">
  <li>Robert E. Coleman, MD, FRCP, FRCPE (medical director  content reviewer/planner) – expert testimony for Novartis </li>
  <li>Amy Furedy, RN, OCN (clinical content/planner) – no relevant financial relationships </li>
  <li>Christi Gray (editorial content reviewer)  – no relevant financial relationships</li>
  <li>Briana Devaser (compliance) – no relevant financial  relationships</li>
</ul><br>

<strong><u>Disclosure Regarding Unlabeled Use</u></strong><br/>
This activity may contain discussion of published  and/or investigational uses of agents that are not indicated by the US Food and  Drug Administration or European Medicines Agency. Please refer to the official  prescribing information for each product discussed for discussions of approved  indications, contraindications, and warnings.<br/><br/>

<strong><u>Disclaimer</u></strong><br/>
Participants have an implied responsibility to use  the newly acquired information to enhance patient outcomes and their own  professional development. The information presented in this activity is not  meant to serve as a guideline for patient management. Any procedures,  medications, or other courses of diagnosis or treatment discussed or suggested  in this activity should not be used by clinicians without evaluation of their  patients&rsquo; conditions and possible contraindications or dangers in use, review  of any applicable manufacturer&rsquo;s product information, and comparison with  recommendations of other authorities.<br/>
